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Simple Summary: In this study we investigated how neuron-derived extracellular vesicles (NDEVs)
mediate neuroimmune regulation in primary cell culture systems. Rat cortical neurons released EVs
that improved microglial survival and inhibited the expression of activation markers on microglia.
Furthermore, NDEVs reduced the LPS-induced proinflammatory response and promoted an anti-
inflammatory response. Thus, neurons critically regulate microglia activity and control inflammation
via EV-mediated neuron–glia communication.
Abstract: Microglia act as the immune cells of the central nervous system (CNS). They play an
important role in maintaining brain homeostasis but also in mediating neuroimmune responses
to insult. The interactions between neurons and microglia represent a key process for neuroim-
mune regulation and subsequent effects on CNS integrity. However, the molecular mechanisms of
neuron-glia communication in regulating microglia function are not fully understood. One recently
described means of this intercellular communication is via nano-sized extracellular vesicles (EVs) that
transfer a large diversity of molecules between neurons and microglia, such as proteins, lipids, and
nucleic acids. To determine the effects of neuron-derived EVs (NDEVs) on microglia, NDEVs were
isolated from the culture supernatant of rat cortical neurons. When NDEVs were added to primary
cultured rat microglia, we found significantly improved microglia viability via inhibition of apoptosis.
Additionally, application of NDEVs to cultured microglia also inhibited the expression of activation
surface markers on microglia. Furthermore, NDEVs reduced the LPS-induced proinflammatory
response in microglia according to reduced gene expression of proinflammatory cytokines (TNF-α,
IL-6, MCP-1) and iNOS, but increased expression of the anti-inflammatory cytokine, IL-10. These
findings support that neurons critically regulate microglia activity and control inflammation via
EV-mediated neuron–glia communication. (Supported by R21AA025563 and R01AA025591).
Keywords: extracellular vesicle; neuron; microglia activation; inflammation; cytokine
1. Introduction
Microglia, one of three types of glial cells found in the CNS, though of myeloid ori-
gin [1], act as the brain’s primary immune cells. As such, microglia play varying roles in
development versus damage, infection, aging, or neurodegenerative diseases [2]. Microglia
display a variety of functional states in the healthy brain but especially with neuropathol-
ogy. For example, under resting conditions, microglia exhibit a ramified morphology
allowing for active surveillance of their environment [3,4]. Upon homeostatic disturbances,
microglia adopt reactive profiles, which range across a spectrum from classical activation
(proinflammatory, M1-like) to alternative activation (anti-inflammatory, M2-like) pheno-
types. Proinflammatory activated “M1-like” microglia produce cytokines, chemokines and
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radical species, which contribute to brain inflammation and further brain damage [5,6].
“M2-like” microglia, however, produce anti-inflammatory cytokines and growth factors
that are associated with reparative processes or resolution of damage [6]. Both the quiescent
and activated states of microglia are controlled by cell-autonomous mechanisms, such as
epigenetic, microRNA and other extracellular signals [2]. Growing evidence supports that
neurons play a crucial role controlling microglia function. Neurons constitutively express
or secrete signaling molecules such as CD200, CD47, and CX3CL1 that bind corresponding
receptors found on microglia (CD200R, C172a, and CX3CR1) to keep microglia in their
quiescent state and/or inhibit their proinflammatory functions [7–9]. In addition to pro-
viding inhibitory signals through the secretion of soluble factors or cell-to-cell contact,
neurons also release extracellular vesicles (EVs) that play an important role in neuron–glia
communication [10–12].
EVs have recently emerged as a means of cell-to-cell communication in the brain [13–15].
EVs are heterogeneous, cell-derived membranous vesicles, that are classified based on their
size and means of biogenesis [13,14]. EVs include endosome-derived exosomes (50–200 nm di-
ameter), irregularly shaped, larger microvesicles (MVs; 100–1000 nm diameter), and apoptotic
bodies (diameters up to 5 um). EVs carry a broad spectrum of proteins, lipids, and a range
of nucleic acids including messenger RNA (mRNA), microRNA (miRNA), and non-coding
RNA [16]. EVs play active roles in development and normal brain function but also in disease
states via horizontal transfer of genetic information, proteins, and lipids between cells without
direct cell-to-cell contact [13–15]. In the CNS, EVs can be released from all cell types including
microglia, oligodendrocytes, astrocytes, and neurons, and have been proposed to contribute
to the neuron–glia communication in various physiological processes of the nervous sys-
tem [17–19]. In particular, exosomes are released by cultured neurons [11,20] and can be
internalized by microglia. Neuronal exosomes suppress the proinflammatory activation of
microglia (M1) via their cargo, especially microRNAs, present in exosomes derived from
spinal cord neurons [12]. However, the effects of NDEVs on microglia activation and function
are not fully understood.
In this study, we hypothesize that NDEVs function as intercellular communicators
between neurons and microglia and provide inhibitory signals under both normal and
immune-activated conditions. Our in vitro studies demonstrate the role of NDEVs in
microglia survival and activation which suggests that NDEVs may regulate microglia acti-
vation and control inflammation. These findings have implications for neurodegenerative
and psychiatric disorders where microglia likely play a role.
2. Materials and Methods
2.1. Cells
All procedures were in accordance with the Guide for the Care and Use of Laboratory
Animals and were approved by the University of Kentucky Institutional Animal Care and
Use Committee prior to the start of experiments. Primary cortical neurons were prepared
and cultured from cortex of embryonic day 18–19 rat embryos as described previously with
modification [21]. Briefly, cortices were dissected out and incubated with 0.25% trypsin in
Hank’s Balanced Salt Solution (Thermo Fisher, Waltham, MA, USA) for 15 min at 37 ◦C,
followed by mechanical dissociation. Single-cell suspensions were plated onto T75 flasks
coated with poly-D-lysine (50 µg/mL, Millipore Sigma, St. Louis, MO, USA) at a density of
5 × 105 cells/cm2 in Neurobasal medium containing B27 supplement (1×, Thermo Fisher)
and penicillin-streptomycin (1×, Thermo Fisher). Cells were incubated at 37 ◦C and 5%
CO2 in a humidified incubator.
Microglia cultures were prepared as described previously [22]. Briefly, cortices were
obtained from postnatal day 2–3 rat pups, stripped of meninges, dissociated with a pipette,
and passed through a 100 µm cell strainer. The cell suspension was seeded into T75 tissue
culture flasks (one rat pup brain per flask) and maintained in Dulbecco’s Modified Eagle’s
Medium (Thermo Fisher, Waltham, MA, USA) supplemented with 10% Fetal Bovine Serum
(Thermo Fisher) and 1% penicillin/streptomycin and grown as a mixed glia culture for
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7–10 days. After mixed glia cultures were completely confluent, flasks were sealed with
parafilm and shaken gently at 100 rpm for 1 h at 37 ◦C to detach microglia. Next, microglia
in suspension were removed from mixed culture and pelleted at 400× g for 5 min at 4 ◦C.
The purity of microglia was determined by immunocytochemical staining (Supplementary
Figure S1). Results showed that over 99.9% of cells were Iba-1+ (microglia-specific marker),
with less than 0.1% of cells Glial Fibrillary Acidic Protein (GFAP+; astrocyte-specific
marker), and no NG2+ or MBP+ (oligodendrocyte-specific markers) cells were observed in
the culture. Cells were then plated at a density of 2 × 105 cells per mL for further treatment.
2.2. Extracellular Vesicle Purification
Neuron-derived extracellular vesicles (NDEVs) were prepared from neuron-conditioned
medium by differential ultracentrifugation as described previously [23]. Briefly, neuron-
conditioned medium was collected from neuronal cultures that were maintained for 5–7 days
in vitro and subjected to serial differential centrifugations at 300× g for 10 min and 2000 × g
for 20 min at 4◦C to remove dead cells and cell debris. Supernatants were then centrifuged
at 10,000× g (Beckman XL 90 ultracentrifuge; 70 TI Rotor; k-factor, 44) for 30 min at 4◦C to
pellet large EVs (L-EVs) [23]. The L-EV pellet was washed with phosphate buffered saline
(PBS) and subjected to an additional centrifugation at 10,000× g for 30 min at 4◦C. Large
EV pellets were then resuspended in PBS and stored at −80 ◦C in aliquots. Small EVs
(S-EVs) remaining in the medium were then pelleted by ultracentrifugation at 100,000× g
(Beckman XL 90 ultracentrifuge; 70 TI Rotor; k-factor, 44) for 70 min at 4◦C. The S-EV pellet
was washed with PBS and then subjected to another centrifugation at 100,000× g (Beckman
XL 90 ultracentrifuge; 70 TI Rotor; k-factor, 44) for 70 min at 4◦C. S-EVs were resuspended in
PBS and stored at −80◦C in aliquots or proteins were extracted with RIPA buffer (Thermo
Fisher) for further analysis by Western blotting.
EV concentration and size distribution were measured using multiple particle tracking
with a Nanosight NS300 (Malvern Panalytical, Malvern, UK) equipped with a 488 nm laser.
Multiple tracking analysis measures the diffusion time of individual nanoparticles to deter-
mine the size and concentration. All samples were measured at least 5 times for a duration
of 60 s each with a minimum of 200 valid tracks per recording. Analysis was performed us-
ing Nanosight 3.4 software. Instrument calibration was verified using 100 nm polystyrene
standard beads. EV protein concentration was measured via a bicinchoninic acid (BCA)
protein assay kit (Pierce, Rockford, IL) following the manufacturer’s instructions: (S-EVs:
0.800 ± 0.322 × 109/mg; L-EVs: 0.291 ± 0.047 × 109/mg).
For in vitro microglia treatment experiments, EVs (0–10 µg/mL) were suspended in
microglia culture medium and added into microglia culture (1.5 to 2 × 105 cells per well)
for 24 h (based on pilot studies), followed by incubation with or without Lipopolysac-
charide (Millipore Sigma) for 8 h for RNA or 24 h for protein. Microglia were collected
24–32 h following EV treatment for flow cytometric analysis or RNA extraction. Microglia
supernatant was collected 48 h following EV treatment for cytokine ELISA.
2.3. Western Blot
Western blots were performed on EV protein or whole neuronal cell lysate extracted
using RIPA buffer containing a protease inhibitor cocktail (Thermo Scientific, Rockford, IL).
Quantification of the isolated protein was achieved using a BCA protein assay according
to the manufacturer’s instructions. A total of 10 µg of protein was boiled in 4× Laemmli
Sample Buffer (Invitrogen) supplemented with 2% β-mercaptoethanol for 5 min before
being loaded for electrophoresis on 10% polyacrylamide gels. The resolved proteins were
then transferred onto nitrocellulose membranes (BioRad, Hercules, CA, USA) with Preci-
sion Plus Protein Dual Color Standards (Bio-Rad, #1610374) on the side well. Membranes
were blocked in 5% skim milk powder in Tris-buffered saline (TBS), and blotted with
primary antibodies (Table 1) overnight at 4◦C on a shaker. Membranes were then incubated
with goat anti-rabbit or goat anti-mouse Ig G IR800 secondary antibody (1:20,000 dilution;
Azure Biosystems, Inc., Dublin, CA, USA) for 1 h at room temperature and then visualized
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using Sapphire Biomolecular Imager (Azure Biosystems). Blots were quantified by ImageJ
software (NIH, Bethesda, MD, USA).
Table 1. Primary antibodies.
Antibody Host Species Cat. Number Dilution Resource
Anti-TSG 101 Rabbit ab125011 1:1000 Abcam
Anti-Flotillin-1 Rabbit #18634 1:1000 Cell Signaling
Anti-Alix Mouse #2171 1:1000 Cell Signaling
Anti-HSC70 Mouse #2171 1:1000 Cell Signaling
Anti-β-Actin Rabbit #4970 1:10,000 Cell Signaling
Anti-CD11b-
FITC Mouse #554982 1:100 BD Bioscience
Anti-CD45-APC Mouse #17-0461-82 1:100 BD Bioscience
Anti-MHC-II-PE Mouse #554929 1:100 BD Bioscience
Anti-CD32-PE Mouse #552189 1:100 BD Bioscience
Anti-CD206 Rabbit #ab64693 1:100 Abcam
Anti-rabbit-PE Donkey #12-4739-81 1:100 BD Bioscience
2.4. MTT Assay
The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is used
to measure cellular metabolic activity as an indicator of cell viability. Microglia were treated
with different concentrations (0, 1, 5, 10 µg/mL) of S-EVs or L-EVs for 24 h. MTT was
added to make up a final concentration of 0.5 mg/mL in medium and cells were incubated
for 1 h at 37◦C in 5% CO2. Cells were dissolved in dimethyl sulphoxide (DMSO) and
absorbance at 490/570 nm was determined in a plate reader (M5, Molecular Devices,
Sunnyvale, CA, USA).
2.5. LDH Assay
Lactate dehydrogenase (LDH) is a cytosolic enzyme released into the cell culture
media upon damage to the plasma membrane. Microglia were incubated with S-EVs for
24 h then LDH release into the medium was measured by a Pierce LDH cytotoxicity Assay
Kit (Thermo Scientific) following exactly the manufacturer’s instructions. Absorbance at
562 nm was measured in an M5 plate reader.
2.6. Propidium Iodide Flow Cytometric Assay
Propidium iodide (PI) flow cytometric assays are well-accepted methods for the
evaluation of cell cycle and apoptosis [24]. Microglia were detached from culture wells
by trypsin and fixed in 66% ethanol on ice. Cells were then incubated in PI (50 µg/mL)
+ RNase (10 µg/mL) at 37◦C in the dark for 30 min. Samples were run on an Attune
Acoustic Focusing Cytometer (ABI, Carlsbad, CA) and PI fluorescence was collected in
FL2 channel. DNA content was quantified in a histogram plot to delineate cells in G1 (2N),
DNA synthesis (2N-4N), mitotic (4N), and apoptotic stages (<2N).
2.7. Microglia Staining and Flow Cytometry
Microglia were scraped from culture wells and suspended in incubation buffer (50 µL;
1 × PBS + 0.1%BSA) for 30 min on ice. Cells were incubated with anti-CD32 (BD Bioscience,
San Jose, CA) to block Fc receptors on microglia for all assays except when used to assess
CD32 immunoreactivity. Cells were then stained with fluorescent conjugated antibodies on
ice for 30 min in order to assess microglia purity (mouse anti-rat CD11b-FITC, #554982, BD
Bioscience, San Jose, CA; mouse anti-rat-CD45-APC, #17-0461-82, eBioscience, San Diego,
CA, USA) and state of M1 activation (mouse anti-rat: MHC-II-PE #554929 and CD32-PE,
#552189, BD Bioscience). For alternative/M2-like activation, cells were incubated in rabbit
anti-rat CD206 (#ab64693, Abcam, Cambridge, MA) for 30 min followed by incubation
with donkey anti-rabbit-PE secondary antibody (#12-4739-81, BD Bioscience) for 30 min.
Cells were washed with PBS, fixed with IC fixation buffer (Invitrogen by ThermoFisher)
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and analyzed on an Attune Acoustic Focusing Cytometer (ThermoFisher). Prior to each
run, the flow cytometer was calibrated with commercially available beads (ThermoFisher).
Fluorescence spillover compensation values were then generated from both non-stained
cell populations as well as single-color staining controls. Isotype controls were also utilized
to exclude any the non-specific binding of the antibodies. For each sample, 1 × 104 events
were collected.
2.8. RNA Isolation and Real-Time PCR
After EVs and/or LPS treatment, microglia were lysed with TRIZOL Reagent (Life Tech-
nologies, Carlsbad, CA, USA) and total RNA was extracted using a mirVana miRNA Isolation
Kit (ThermoFisher, Waltham, MA, USA) according to the manufacturer’s instructions. Real-
time RT-PCR was performed with Assays-on-Demand primers [TNF-α (Rn00562055_m1), IL-6
(Rn01410330_m1), MCP-1 (Rn00580555_m1), iNOS (Rn00561646_m1), IL-10 (Rn01483988_g1),
Applied Biosystems Inc.], using a one-step quantitative Real-time RT-PCR system (Ther-
moFisher, Waltham, MA, USA). The housekeeping gene, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH, Rn01462661_g1) was used as an internal control. Data were analyzed
by calculating the differences between the delta cycle values for the EV/LPS treatments and
control conditions (double delta cycle analysis) as previously described [25]. Results were
expressed as fold difference as compared to no EV treatment control.
2.9. Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA for TNF-α and IL-6 were performed according to the manufacturer’s instruc-
tions (DuoSet ELISA for TNF-α and IL-6, R&D Systems, Minneapolis, MN, USA). Briefly,
96-well plates were coated with capture antibodies for TNF-a or IL-6 in PBS overnight
at room temperature (RT). Plates were blocked with 1% bovine serum albumin (BSA)
in PBS for 2 h at RT, following which samples or standards were added and incubated
for 2 h at RT or overnight at 4 ◦C. Adhering antigen was detected by incubation with
biotin-conjugated detection antibody for 2 h at RT followed by horseradish peroxidase-
conjugated streptavidin for 20 min. Then, 100 µL of Substrate Solution (1:1 mix of H2O2
and Tetramethylbenzidine) were added to each well, followed by 50 µL of Stop Solution
(2N H2SO4). Optical density was determined using a microplate reader (BioTec, Winoosk,
VT, USA) set to 450 nm and wavelength correction set to 540 nm.
2.10. Statistical Analysis
All of the resulting raw data were compiled in Excel and then graphed and analyzed
in Prism (v7, GraphPad Software, San Diego, CA, USA). Unless stated otherwise, all values
are reported as mean ± S.D. with n indicating the number of replicates. Flow cytome-
try data were compared via Student’s t-test (for two groups) or one-way ANOVA with
Holm–Sidak’s posthoc test (all groups versus control) or Tukey’s (3 groups, all pairwise
comparisons) posthoc test. Data for real time RT-PCR were compared using two-way
ANOVA for EV treatment and LPS as factors with Tukey’s posthoc tests. Statistical signifi-
cance was accepted at a p < 0.05.
3. Results
3.1. EVs Derived from Neurons Improve Microglia Survival
To determine if NDEVs contribute to neuron–microglia intercellular communication,
we obtained EVs through serial steps of ultracentrifugations from rat cortical neuronal
cultures as described in Section 2. The size distribution of small or large EVs (S-EVs or
L-EVs) was analyzed by nanoparticle tracking analysis (NTA, Figure 1A). NTA revealed
that S-EVs secreted from neurons were 158.3 ± 75.9 nm in size, with a peak diameter
of about 106 nm (Figure 1A). The L-EV isolation was more heterogenous, with multiple
peak diameters from 124 to 768 nm (Figure 1A). We then examined the characteristic
markers, including Alix, flotillin, TSG101, and HSC70 by Western blotting (Figure 1B). The
characteristic markers Alix, flotillin and TSG 101 were highly expressed in S-EVs, while
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HSC70 was expressed in both S-EVs and L-EVs. These results confirmed that the particles
we extracted were EVs.
Figure 1. (A). Particle size distribution of small- and large-EVs isolated from cultured primary
neurons by Nanopartical tracking analysis showing the size versus concentration of particles. (B). The
Western blot analysis of characteristic markers of EVs. The characteristic markers (Alix, TSG101 and
Flotillin) were more highly expressed in S-EVs than L-EVs and neuronal cell lysate. Band intensity
was analyzed by ImageJ software as shown in Table 2.
Table 2. Quantification for Western blot.
Antibody Cell Lysate Large-EVs Small-EVs
Anti-TSG 101 1 0.69 3.20
Anti-Flotillin-1 1 9.42 41.78
Anti-Alix 1 3.30 35.70
Anti-HSC70 1 0.82 1.08
Protein levels for cell lysate (CL) were normalized to 1.0 and data were relative to CL.
To determine the effect of NDEVs on microglia, primary microglia were treated with
of different concentrations of S-EVs (0–10 µg/mL) for 24 h. S-EVs increased microglia cell
viability in a dose-dependent manner as indicated by MTT assay [F(6,23) = 283.2; p < 0.0001]
by 1.32 ± 0.12 fold for 1 µg/mL (p < 0.05), 3.5 ± 0.22 fold for 5 µg/mL (p < 0.0001), and
3.75 ± 0.30 fold for 10 µg/mL (p < 0.0001; Figure 2A). Importantly, this effect is S-EV specific
as L-EVs isolated from neuronal culture do not increase microglial cell viability (Figure 2A).
To determine if the S-EV-mediated increase of microglial cell viability is through an increase
in cell survival, we determined extracellular LDH in the supernatant of microglia treated
with or without neuronal S-EVs. Results showed that S-EVs reduced LDH release from
microglia [F(2,7) = 548.7; p < 0.0001] with a 16% reduction for 1 µg/mL, (Holm–Sidak:
p < 0.0001) and 25% reduction for 10 µg/mL (p < 0.0001; Figure 2B). To further confirm that
the effect of neuronal S-EVs on microglia is through an increase in cell survival but not
through inducing cell proliferation, we determined cell cycle status by measuring DNA
content using Propidium iodide (PI) staining combined with flow cytometric analysis. PI
flow cytometry has also been used widely for the evaluation of cell apoptosis [24]. PI flow
cytometry showed neither S-EVs nor L-EVs change cell populations undergoing DNA
synthesis (2N-4N), which suggests that they do not promote microglial cell proliferation.
In addition, S-EV treatment reduced the apoptotic cell population, <2N, from 24.4 ± 6.0%
to 2.9 ± 1.4% [F(2,7) = 32.37; p = 0.0003; Tukey’s p = 0.0004], while L-EVs had little effect on
the apoptotic cell population (22.2 ± 3.0%, Figure 2C,D). These results suggest that S-EVs
protect microglial cells from apoptosis but do not increase microglial proliferation.
3.2. EVs Derived from Neurons Impact the Activity of Microglia
To determine the effect of neuronal EVs on microglia activity, primary microglia
cultures were treated with NDEVs purified from rat cortical neuron culture. Twenty-four
hours later, microglia were scraped from culture dishes and stained with microglia surface
antigens. Fixed cells were then analyzed by flow cytometry. Cells were stained for CD11b
(a component of complement receptor 3) to confirm cell purity (Figure 3A). Consistent
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with immunocytochemical staining (Supplementary Figure S1), these isolated cells were
highly enriched for microglia. CD11b is expressed constitutively by microglia and increases
to a greater extent upon microglia activation. Results showed that S-EVs reduced mean
fluorescence intensity (MFI) of CD11b by 21.8 ± 8.3% (Figure 3B). Microglia activation
states can be classified as either M1-like or M2-like based on changes in morphology and/or
expression of phenotypic, cell surface antigens [26–28]. For example, phenotypic markers
such as major histocompatibility complex (MHC) II and CD32 have been used to identify
M1-like cells [29]. M2-like microglia, on the other hand, express CD206 (macrophage
mannose receptor 1) on the cell membrane. Results showed that S-EV treatment reduced
M1-like microglia as indicated by a decrease in the expression frequency of MHC-II+ cells
(9.7 ± 1.2% in controls vs. 2.8 ± 0.4% in S-EV treated cells, p < 0.001; Figure 3F) and CD32+
cells (21.9 ± 3.2% in controls vs. 10.7 ± 6.2% in S-EV treated cells, p = 0.018; Figure 3G).
S-EV treatment also decreased the MFI of MHC-II by 35.9 ± 3.2% (Figure 3C) and CD32
by 20.8 ± 11.7%. L-EVs, however, had little effect on the MFI of CD11b or CD32, or the
expression frequency of CD32 (Supplemental Figure S2). We also observed a decrease of
M2-like microglia as indicated by decrease of CD206+ cells: 11.3 ± 2.0% in controls vs.
5.0 ± 0.3% in S-EV treated cells (p < 0.001; Figure 3H), as well as a 37.6 ± 7.3% reduction of
CD206 MFI (Figure 3E).
Figure 2. (A) Primary microglia were treated with NDEVs purified from rat neuronal cultures for
24 h and cell viability was detected by MTT assay. (B) Cell supernatant was collected for LDH assay.
Data in A and B are shown as fold of control. (C) Flow cytometric analysis of DNA content by PI
staining. (D) Data are shown as % of cells in G1 stage (2N), DNA synthesis (2N-4N) and mitotic (4N)
or apoptotic (<2N). Data are mean values ± SD of three independent experiments.; * p < 0.05 versus
control via post test. # p < 0.05 versus S-EV via post test.
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Figure 3. Primary microglia were treated with NDEVs purified from rat neuronal cultures. The
expression of microglia/macrophage phenotypic markers, CD11b, CD32, MHC-II and CD206, were
detected using an Attune Acoustic Focusing Cytometer. (A) Isolated microglia express CD11b.
(B–H) Data presented show mean fluorescent intensity (MFI) of CD11b (B), MHC-II (C), CD32 (D),
and CD206 (E) expression or percentage of MHC-II (F), CD32 (G), and CD206 (H) expression on
microglia with or without S-EV treatment. Data are mean values ± SD of three to six independent
experiments. * p < 0.05 versus control.
3.3. Neuronal EVs Suppress LPS-Induced Microglia Activation
Lipopolysaccharide (LPS, the major component of the outer membrane of Gram-
negative bacteria) activates microglia/macrophages and induces proinflammatory acti-
vation, which produces proinflammatory cytokines and inducible nitric oxide synthase
(iNOS) [30]. Primary microglia were pre-incubated with S-EVs for 24 h and then treated
with LPS (0.1–10 ng/mL) for 8 h. Total RNA were extracted, and the levels of mRNA en-
coding pro-inflammatory cytokine/chemokines (IL-6, TNF-α, and MCP-1), iNOS, and anti-
inflammatory cytokine (IL-10) were quantified by real-time RT-PCR. Results showed that
LPS induced concentration-dependent increases of TNF-α, IL-6, MCP-1, IL-10, and iNOS
expression indicated by main effects of LPS concentrations (Table 3). S-EV pre-treatment in-
hibited LPS-induced proinflammatory cytokines TNF-α and IL-6 (Figure 4A,B), chemokine
MCP-1 (Figure 4C), and iNOS expression (Figure 4D), but promoted anti-inflammatory
cytokine, IL-10, expression in microglia as indicated by main effects of EV treatment and
a significant interaction of LPS concentration and EV treatment (Table 3; Figure 4E). To
determine if L-EVs similarly suppressed LPS-induced microglia activation as S-EVs, pri-
mary microglia were pre-incubated with S-EVs or L-EVs for 24 h and then treated with
LPS (1 ng/mL) for 8 h. L-EV pre-treatment did not inhibit LPS-induced TNF-α, MCP-1,
or iNOS expression, and did not promote IL-10 expression in microglia (Supplementary
Figure S3). In addition, primary microglia were pre-incubated with S-EVs for 24 h and then
treated with LPS for 24 h. Cytokines (TNF-α and IL-6) released into culture supernatant
were determined by ELISA (Figure 5). Results showed that S-EV pre-treatment inhibited
LPS-induced proinflammatory cytokine TNF-α and IL-6 expression. These data suggest
that neuronal EVs modulate innate immunity in the brain, dampening pathogenic M1
microglia, and point to a possible mediator for suppression of neuroinflammation.
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Table 3. Statistics for Figure 4.
Target ME [LPS] ME [S-EV Tx] Interaction
TNF-α F(3,16) = 124.5; p < 0.0001 F(1,16) = 122.5; p < 0.0001 F(3,16) = 42.4; p < 0.0001
IL-6 F(3,16) = 988.4; p < 0.0001 F(1,16) = 406.5; p < 0.0001 F(3,16) = 239.3; p < 0.0001
MCP-1 F(3,16) = 288.4; p < 0.0001 F(1,16) = 163.9; p < 0.0001 F(3,16) = 82.9; p < 0.0001
iNOS F(3,13) = 1133.0; p < 0.0001 F(1,13) = 643.8; p < 0.0001 F(3,13) = 229.4; p < 0.0001
IL-10 F(3,14) = 235.3; p < 0.0001 F(1,14) = 1239.2; p < 0.0001 F(3,14) = 53.75; p < 0.0001
Main effect (ME); concentration of LPS [LPS]; S-EV treatment [S-EV Tx].
Figure 4. Total RNA was extracted from EV-treated microglia. mRNA expression of TNF-α (A), IL-6 (B), MCP-1 (C), iNOS
(D) and IL-10 (E) was determined by real-time RT-PCR and presented as folds of control. PCR was run in triplicate and
data were presented as mean fold of control ± SD. Data represented three independent experiments and was analyzed by
ANOVA. Statistics are listed in Table 3. * p < 0.05 versus respective control with LPS.
Figure 5. Primary microglia were pre-incubated with S-EVs for 24 h and then treated with LPS for
24 h. Culture supernatant was collected to determine cytokine [TNF-α (A) and IL-6 (B)] expression
by ELISA. Data represented three independent experiments and was analyzed by ANOVA. * p < 0.05
versus control. # p < 0.05 versus non S-EV.
4. Discussion
The interactions between neurons and microglia represent a key process of neu-
roimmune regulation with potential implications for the regulation of CNS integrity in
neurodegenerative and psychiatric disease [31–34]. Secretion of exosomes from cultured
primary neurons has been observed previously [11,20]. In this study we demonstrated
the potential role of neuron derived EVs as a means of intercellular signaling in neuron–
microglia communication. We isolated EVs from rat cortical neuronal culture and exposed
microglia to these NDEVs. Here, we show that supernatants of these primary cortical
culture contained small EVs of a composition and size typical of exosomes. S-EVs promoted
microglia survival and inhibited microglia activation marker expression, both effects of
which were S-EV specific as large EVs did not have the same effects on microglia. We also
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found that incubating microglia with S-EVs inhibited LPS-induced pro-inflammatory cy-
tokine expression. These results indicate that S-EVs released by neurons regulate microglia
reactivity and control LPS-induced proinflammatory microglia activation. Considering the
importance of microglia reactivity in both physiological and pathological conditions, these
results suggest a new pathway of microglia regulation.
Our understanding of the role of exosomes as an important mechanism for intercellular
communication in the CNS is just beginning to emerge [13,17,18,35]. Exosomes facilitate
the transfer of information between cells through their release and shuttling of a cargo of
various signaling proteins and coding and/or regulatory RNAs, that are then taken up
by target cells. Exosomes, therefore, not only play critical roles in physiological processes,
such as synaptic function, nerve regeneration, and neuronal development, but are also
implicated in the pathogenesis of a variety of neurodegenerative disorders. For example,
exosomes secreted from a variety of cell types have been shown to contain prions or
beta-amyloid peptides, which suggests their role in the transmission of toxic proteins
in neurodegenerative conditions [36,37]. In addition, they may also contribute to the
neuroimmune activities through the shuttling of signaling molecules between neurons and
glia [17,18,35].
Neuron–glia communication has been shown to play a critical role in the nervous
system in both normal physiological as well as pathological conditions. There is increasing
evidence to indicate that neurons are not merely victims of (over)activated microglia but
rather control microglial function and activity [2,7]. For example, neurons constitutively
express “Off” signals which are thought to keep microglia in a quiescent state. This pro-
cess aids in maintaining tissue homeostasis, but also restricts pro-inflammatory microglia
activity to prevent further damage to the brain [7]. Most of these effects are through the ex-
pression of signaling molecules on plasma membranes (CD200, CD47, etc.) or the secretion
of soluble ligands (CX3CL1) [2]. Our work further demonstrated that neurons release EVs
that may have significant roles in maintaining a homeostatic phenotype of microglia and
regulating their activation beyond these mechanisms. Our results showed that extracel-
lular particles with the characteristics of EVs (size distribution and characteristic marker
expression) are involved in neuron-to-microglia communication and may deliver cargo
from neurons to microglia as evidenced by the functional change of microglia (improved
survival, maintaining microglia quiescence and inhibition of over-activation) after S-EV
treatment. Thus, the results of this study demonstrate that constitutively produced NDEVs
represent a new means of regulating microglia function.
Indeed, NDEVs have been shown to elicit various physiological responses in target
microglia. For example, more microglia survived in vitro if they had received small EVs,
which suggests that NDEVs may play a protective role and increase microglia tolerance
to stress. The roles of NDEVs in control of microglial activation can be divided into two
mechanisms: to stabilize microglia in their quiescent state by inhibition of activation
mechanisms (as suggested by reduced activation marker expression) in normal conditions
and/or antagonize LPS-induced proinflammatory activity. Microglial activation in the
normal, healthy brain is constrained by “Off” signals that are constitutively expressed
by neurons in the normal brain microenvironment [2,7]. Without these in vivo inhibitory
signals and under the exposure of fetal bovine serum in the culture media, microglia in
culture are a mixture of M1 or M2-like and non-activated cell populations as indicated
by the M1 marker (MHC-II and CD32) and M2 marker (CD206) expression (Figure 2).
Here, we showed that small NDEVs inhibit activation markers expressed in microglia
under normal culture conditions, which suggests that EVs may contribute to these “Off”
signals in the normal brain microenvironment [2]. Under pathological insults, microglia
respond as either neurotoxic or neuroprotective depending on the various signals in the
microenvironment [2]. For example, LPS induces a neurotoxic microglia response through
the release of proinflammatory cytokines and inducing oxidative stress [30]. To further
evaluate if NDEVs regulate microglia activation under LPS-induced proinflammatory
activation, microglia were exposed to S-EVs and stimulated with LPS. Our results showed
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that the gene expression pattern is modified in LPS-activated microglia that received S-EVs:
LPS-induced pro-inflammatory cytokines/chemokine (IL-6, TNF-α, and MCP-1) and iNOS
gene expression are inhibited, consistent with a recent study in spinal cord [12]. While
mRNA expression may not always mirror protein expression, we confirmed that S-EVs
inhibit LPS-induced proinflammatory cytokine (TNF-α and IL-6) secretion with ELISA
(Figure 5).
We also demonstrated that NDEVs increased a potent, anti-inflammatory cytokine, IL-
10, gene expression. IL-10 limits host inflammatory response to pathogens thus preventing
inflammation. Although it has been shown that IL-10 inhibits LPS-induced proinflamma-
tory cytokine secretion [38], whether or not IL-10 contributes to NDEV-mediated inhibition
of LPS-induced proinflammatory cytokine production will need further investigation. In
addition, we observed that S-EVs change microglia phenotypes from activated M1 or
M2-like microglia to non-activated states in normal culture conditions, however, it remains
unknown whether NDEVs inhibit LPS-induced proinflammatory cytokines and iNOS
production through change a microglia phenotype or through the regulation of specific
genetic pathways. The regulation of microglia phenotype and cytokine production may
occur through different mechanisms. A thorough RNA sequencing analysis of regulated
genes will be helpful to extend this work into mechanistic directions. Subsequent studies
in cytokine knockout models would then be important for determining the specific ge-
netic pathway effect versus phenotypic output. Thus, NDEVs dampen microglia immune
reactivity induced by LPS and prevent the development of excessive and uncontrolled
stimulation of microglia that may lead to secondary neuronal damage.
The underlying mechanism behind the NDEV effect on microglia is not fully under-
stood, but their various cargos provide clues to these effects. Neuronal EVs may express
the inhibitory signaling molecules on their membrane, and thus keep microglia inactivated.
The expression of these signaling molecules in neuronal EVs and their roles in maintaining
a homeostatic phenotype of microglia needs further confirmation. In addition to protein
cargo, miRNAs may also contribute to the effects of NDEVs on microglia. A recent study
demonstrated that neuronal exosomes shuttle microRNA-124-3p to microglia and mediate
the suppression of M1 microglia and A1 astrocyte activation after spinal cord injury [12].
Our preliminary miRNA sequencing analysis reveals that miRNAs known to regulate
microglia/macrophage function such as miR-125b, miR-9a, miR-let-7a, miR-let-7c, miR-30a,
and miR-181c are highly expressed in NDEVs [39] (unpublished observations; Peng et al.,
in preparation). Whether or not NDEVs shuttle these miRNAs to microglia and mediate
the suppression of LPS-mediated microglia activation will need further investigation. The
distinct function of S-EVs and L-EVs on microglia may be attributed to their differential
cargos. Proteomic analyses have indicated that exosomes are enriched with receptors and
kinases that mediate signaling in immune regulation, whereas MVs are more implicated in
protein translation [13,40]. Although current EV isolation techniques do not distinguish
exosomes versus MVs, a thorough analysis of the cargos (both protein and nuclei acid)
of S-NDEVs and L-NDEVs will help to identify the components that contribute to their
differential function on microglia. Future work combining next-generation RNA sequenc-
ing, proteomics, and bioinformatic analysis is needed to identify the specific RNAs and
proteins present in NDEVs that mediate this effect of NDEVs on microglia function.
5. Conclusions
In summary, this study investigated a novel regulatory mechanism in neuron-to-
microglia communication. These data provide new insight into EV-mediated regulation
of microglia function and activation under pro-inflammatory conditions. The specific
components in EVs that contributed to these effects are unclear, but neuronal EVs contain
numerous signaling molecules, including proteins and RNAs, that play significant roles in
neuron-to-microglia communication. Ultimately, these results contribute to our understand-
ing of the mechanisms of neuronal regulation of microglia activation, a phenomenon that
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has major implications for our understanding of—and the development of new therapies
for—neurodegenerative and psychiatric disease.
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microglia activity, Figure S3: To determine if L-EVs had the similar effects to suppress LPS-induced
microglia activation as S-EVs, primary microglia were pre-incubated with S-EVs or L-EVs for 24 h
and then treated with LPS (1 ng/ml) for 8 h, Table S1: Primary antibodies.
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